Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Cyclically Adjusted Revenue per Share: ¥1.58 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603811 Zhejiang Cheng Yi Pharmaceutical Co Ltd SHSE:603811
86 GF Score
Price ¥7.19
GF Value ¥7.64
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Zhejiang Cheng Yi Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Zhejiang Cheng Yi Pharmaceutical Co SHSE:603811 -1.78% 86 Cyclically Adjusted Revenue per Share is ¥1.58 as of Jun. 2026. GuruFocus rates SHSE:603811 with a GF Score™ of 86/100 and a GF Value™ of ¥7.64 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zhejiang Cheng Yi Pharmaceutical Co's adjusted revenue per share for the three months ended in Jun. 2026 was ¥0.501. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥1.58 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Zhejiang Cheng Yi Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-31), Zhejiang Cheng Yi Pharmaceutical Co's current stock price is ¥7.19. Zhejiang Cheng Yi Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ¥1.58. Zhejiang Cheng Yi Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 4.55.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zhejiang Cheng Yi Pharmaceutical Co was 7.91. The lowest was 2.93. And the median was 4.68.


Zhejiang Cheng Yi Pharmaceutical Co  (SHSE:603811) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zhejiang Cheng Yi Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.19/1.58
=4.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zhejiang Cheng Yi Pharmaceutical Co was 7.91. The lowest was 2.93. And the median was 4.68.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zhejiang Cheng Yi Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Zhejiang Cheng Yi Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zhejiang Cheng Yi Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Cheng Yi Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Zhejiang Cheng Yi Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.48 1.53

Zhejiang Cheng Yi Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.50 1.51 1.53 1.56 1.58

SHSE:603811 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Cheng Yi Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Cheng Yi Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Cheng Yi Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zhejiang Cheng Yi Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


SHSE:603811
86GF Score
Zhejiang Cheng Yi Pharmaceutical Co Ltd SHSE:603811
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Cheng Yi Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zhejiang Cheng Yi Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.501/116.0564*116.0564
=0.501

Current CPI (Jun. 2026) = 116.0564.

Zhejiang Cheng Yi Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.184 102.400 0.209
201612 0.313 102.600 0.354
201703 0.238 103.200 0.268
201706 0.144 103.100 0.162
201709 0.168 104.100 0.187
201712 0.373 104.500 0.414
201803 0.377 105.300 0.416
201806 0.394 104.900 0.436
201809 0.457 106.600 0.498
201812 0.318 106.500 0.347
201903 0.316 107.700 0.341
201906 0.586 107.700 0.631
201909 0.491 109.800 0.519
201912 0.399 111.200 0.416
202003 0.339 112.300 0.350
202006 0.379 110.400 0.398
202009 0.404 111.700 0.420
202012 0.545 111.500 0.567
202103 0.381 112.662 0.392
202106 0.411 111.769 0.427
202109 0.362 112.215 0.374
202112 0.360 113.108 0.369
202203 0.338 114.335 0.343
202206 0.363 114.558 0.368
202209 0.329 115.339 0.331
202212 0.391 115.116 0.394
202303 0.319 115.116 0.322
202306 0.391 114.558 0.396
202309 0.300 115.339 0.302
202312 0.464 114.781 0.469
202403 0.334 115.227 0.336
202406 0.428 114.781 0.433
202409 0.379 115.785 0.380
202412 0.407 114.893 0.411
202503 0.405 115.116 0.408
202506 0.523 114.907 0.528
202509 0.417 115.471 0.419
202512 0.469 115.832 0.470
202603 0.454 116.303 0.453
202606 0.501 116.056 0.501

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥1.58 mean?
Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) has a Cyclically Adjusted Revenue per Share of ¥1.58 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zhejiang Cheng Yi Pharmaceutical Co and its competitors.
Is Zhejiang Cheng Yi Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Zhejiang Cheng Yi Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥1.58. Overall, Zhejiang Cheng Yi Pharmaceutical Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Cheng Yi Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Zhejiang Cheng Yi Pharmaceutical Co's Cyclically Adjusted Revenue per Share of ¥1.58 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zhejiang Cheng Yi Pharmaceutical Co and its competitors. Zhejiang Cheng Yi Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is ¥1.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Cheng Yi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.64, compared to a current price of ¥7.19 — trading 5.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥1.58. Zhejiang Cheng Yi Pharmaceutical Co's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811), the current Cyclically Adjusted Revenue per Share is ¥1.58 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Cheng Yi Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥7.19 is trading 5.9% below its estimated GF Value™ of ¥7.64. GuruFocus considers Zhejiang Cheng Yi Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603811:

  • Cyclically Adjusted Revenue per Share: ¥1.58
  • GF Value™: ¥7.64 vs. price of ¥7.19 (5.9% below fair value)
  • GF Score™: 86/100 with 3 warning signs

No single metric tells the full story. See the SHSE:603811 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Cheng Yi Pharmaceutical Co Business Description

Address Lane 988, Shenhong Road, 7th Floor, No. 9, Building 20, Fuli Yuedu, Minhang District, Shanghai, CHN, 201100
Zhejiang Cheng Yi Pharmaceutical Co Ltd is a pharmaceutical company that produces capsules, injections, tablets, APIs, and pharmaceutical intermediates in China. Its main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, Gastrodin raw materials, ribavirin and purine raw materials, and so on.
86GF Score

Get the complete analysis for SHSE:603811

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.19
Price
¥7.64
GF Value